The trials and tribulations of pediatric drug trials

Neurology

Volumn 65, Issue 9, 2005, Pages 1348-1349

  Shinnar, Shlomo ^a,c   Pellock, John M ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; OXCARBAZEPINE;

AGE; CHILD; CHILD HEALTH CARE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; FOCAL EPILEPSY; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; MEDICAL SOCIETY; PEDIATRICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 27644453470     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000183475.81594.29     Document Type: Editorial

References (8)

1. Sheridan PH, Jacobs MP. The development of antiepileptic drugs for chilren. Report from the NIH Workshop, Bethesda, MD, February 17-18, 1994. Epilepsy Res 1996;23:87-92.
2. Pellock JM. Managing pediatric epilepsy syndrome with new antiepileptic drugs. Pediatrics 1999;100:1106-1113.
3. Pifla-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005;65:1370-1375.
4. French JA, Kanner AM, Bautista MD, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 2004;62:1261-1273.
5. French JA, Kanner AM, Bautista MD, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004;62:1252-1260.
6. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms. Report of the American Academy of Neurology and Child Neurology Society. Neurology 2004;62:1668-1681.
7. Nordli DR Jr. Diagnostic difficulty in infants and children. J Child Neurol 2002;17:S28-S35.
8. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001;57:864-871.